8-K
filed November 21, 2023, 6:59 PM ET
CIK 0001694665
other material
confidence high
sentiment negative
materiality 0.95
Evelo Biosciences to dissolve; board and CEO resign, new wind-down officer appointed
Evelo Biosciences, Inc.
- Board of directors resigned Nov 20, 2023; board reduced to one director (Craig R. Jalbert).
- CEO Simba Gill and CFO Marella Thorell stepped down; employment ends Dec 1 with severance.
- Craig R. Jalbert appointed President, Secretary, and sole director to lead wind-down and dissolution.
- Company seeks stockholder approval for dissolution; expects Nasdaq delisting and SEC deregistration.
- Engaged Rock Creek Advisors to monetize assets; no viable alternative to dissolution found.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Craig R. Jalbert was appointed as Director at Evelo Biosciences, Inc..
- Action
- appointed
- Role
- Director
Exact text from the filing
Mr. Jalbert was also appointed as sole member of the Board as a Class II director, effective upon the aforementioned directors’ resignations, with a term that expires upon the election and qualification of his successor or until his earlier resignation or removal.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Tonya Williams resigned as Director at Evelo Biosciences, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
On November 20, 2023, in connection with the Dissolution (as defined below), each of Juan Andres, Balkrishan (Simba) Gill, Ph.D., Jose-Carlos Gutiérrez-Ramos, Ph.D., Jeffrey R. Moore, Alexander C. Reynolds, Robert L. Rosiello and Tonya Williams notified Evelo Biosciences, Inc. (the “Company,” “we,” “us,” “our,” and “Evelo”) of their resignation from the Board of Directors (the “Board”) of the Company and all committees thereof, effective upon the Company’s acceptance of such resignation.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Jose-Carlos Gutiérrez-Ramos resigned as Director at Evelo Biosciences, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
On November 20, 2023, in connection with the Dissolution (as defined below), each of Juan Andres, Balkrishan (Simba) Gill, Ph.D., Jose-Carlos Gutiérrez-Ramos, Ph.D., Jeffrey R. Moore, Alexander C. Reynolds, Robert L. Rosiello and Tonya Williams notified Evelo Biosciences, Inc. (the “Company,” “we,” “us,” “our,” and “Evelo”) of their resignation from the Board of Directors (the “Board”) of the Company and all committees thereof, effective upon the Company’s acceptance of such resignation.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Alexander C. Reynolds resigned as Director at Evelo Biosciences, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
On November 20, 2023, in connection with the Dissolution (as defined below), each of Juan Andres, Balkrishan (Simba) Gill, Ph.D., Jose-Carlos Gutiérrez-Ramos, Ph.D., Jeffrey R. Moore, Alexander C. Reynolds, Robert L. Rosiello and Tonya Williams notified Evelo Biosciences, Inc. (the “Company,” “we,” “us,” “our,” and “Evelo”) of their resignation from the Board of Directors (the “Board”) of the Company and all committees thereof, effective upon the Company’s acceptance of such resignation.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Jeffrey R. Moore resigned as Director at Evelo Biosciences, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
On November 20, 2023, in connection with the Dissolution (as defined below), each of Juan Andres, Balkrishan (Simba) Gill, Ph.D., Jose-Carlos Gutiérrez-Ramos, Ph.D., Jeffrey R. Moore, Alexander C. Reynolds, Robert L. Rosiello and Tonya Williams notified Evelo Biosciences, Inc. (the “Company,” “we,” “us,” “our,” and “Evelo”) of their resignation from the Board of Directors (the “Board”) of the Company and all committees thereof, effective upon the Company’s acceptance of such resignation.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Craig R. Jalbert was appointed as President at Evelo Biosciences, Inc..
- Action
- appointed
- Role
- President
Exact text from the filing
On November 20, 2023, the Board appointed Craig R. Jalbert, age 62, as the Company’s President and Corporate Secretary and as Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer, in each case, effective as of 12:00 a.m., Eastern Time, on November 21, 2023.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Simba Gill resigned as Director at Evelo Biosciences, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
On November 20, 2023, in connection with the Dissolution (as defined below), each of Juan Andres, Balkrishan (Simba) Gill, Ph.D., Jose-Carlos Gutiérrez-Ramos, Ph.D., Jeffrey R. Moore, Alexander C. Reynolds, Robert L. Rosiello and Tonya Williams notified Evelo Biosciences, Inc. (the “Company,” “we,” “us,” “our,” and “Evelo”) of their resignation from the Board of Directors (the “Board”) of the Company and all committees thereof, effective upon the Company’s acceptance of such resignation.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Robert L. Rosiello resigned as Director at Evelo Biosciences, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
On November 20, 2023, in connection with the Dissolution (as defined below), each of Juan Andres, Balkrishan (Simba) Gill, Ph.D., Jose-Carlos Gutiérrez-Ramos, Ph.D., Jeffrey R. Moore, Alexander C. Reynolds, Robert L. Rosiello and Tonya Williams notified Evelo Biosciences, Inc. (the “Company,” “we,” “us,” “our,” and “Evelo”) of their resignation from the Board of Directors (the “Board”) of the Company and all committees thereof, effective upon the Company’s acceptance of such resignation.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Marella Thorell departed as Chief Financial Officer at Evelo Biosciences, Inc..
- Action
- ceased serving
- Role
- Chief Financial Officer
Exact text from the filing
On November 20, 2023, in connection with the Dissolution, Simba Gill ceased serving as the Company’s President, Chief Executive Officer, principal executive officer and president, and Marella Thorell ceased serving as the Company’s Chief Financial Officer, Secretary, Treasurer, principal financial officer and principal accounting officer, in each case, effective as of 11:59 p.m., Eastern Time, on November 20, 2023.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Juan Andres resigned as Director at Evelo Biosciences, Inc..
- Action
- resigned
- Role
- Director
Exact text from the filing
On November 20, 2023, in connection with the Dissolution (as defined below), each of Juan Andres, Balkrishan (Simba) Gill, Ph.D., Jose-Carlos Gutiérrez-Ramos, Ph.D., Jeffrey R. Moore, Alexander C. Reynolds, Robert L. Rosiello and Tonya Williams notified Evelo Biosciences, Inc. (the “Company,” “we,” “us,” “our,” and “Evelo”) of their resignation from the Board of Directors (the “Board”) of the Company and all committees thereof, effective upon the Company’s acceptance of such resignation.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Simba Gill departed as Chief Executive Officer at Evelo Biosciences, Inc..
- Action
- ceased serving
- Role
- Chief Executive Officer
Exact text from the filing
On November 20, 2023, in connection with the Dissolution, Simba Gill ceased serving as the Company’s President, Chief Executive Officer, principal executive officer and president, and Marella Thorell ceased serving as the Company’s Chief Financial Officer, Secretary, Treasurer, principal financial officer and principal accounting officer, in each case, effective as of 11:59 p.m., Eastern Time, on November 20, 2023.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.